A new vaccine strategy using a stable measles protein
Thermostable measles fusion glycoprotein as a new vaccine strategy
This study is working on a new measles vaccine that is safe for people with weakened immune systems and can be easily shared around the world without needing to be kept cold, especially helping to protect children under 11 from measles and its serious effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11131483 on NIH RePORTER |
What this research studies
This research focuses on developing a new vaccine strategy for measles that is safe for immune-compromised individuals and can be easily distributed worldwide without refrigeration. The approach involves creating a thermostable version of the measles fusion protein, which has shown promise in generating protective immunity and neutralizing antibodies. By testing this new vaccine in vulnerable populations, the research aims to address the resurgence of measles and its associated complications, particularly in children under 11 years old.
Who could benefit from this research
Good fit: Ideal candidates for this research include children under 11 years old and individuals with compromised immune systems who are at risk for severe measles infection.
Not a fit: Patients who are not at risk for measles or those who have already been vaccinated against measles may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safe and effective vaccination option for children and immune-compromised individuals, significantly reducing the incidence of measles and its complications.
How similar studies have performed: Other research has successfully developed similar thermostable vaccines, indicating that this approach has clinical validity.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Porotto, Matteo — Columbia University Health Sciences
- Study coordinator: Porotto, Matteo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.